Vertex Pharmaceuticals (NASDAQ:VRTX) Stock Price Expected to Rise, TD Cowen Analyst Says

Vertex Pharmaceuticals (NASDAQ:VRTX) had its target price hoisted by equities research analysts at TD Cowen from $550.00 to $575.00 in a report issued on Tuesday, Benzinga reports. The firm presently has a “buy” rating on the pharmaceutical company’s stock. TD Cowen‘s price objective suggests a potential upside of 7.10% from the stock’s current price.

Several other equities analysts also recently issued reports on VRTX. Evercore upped their price objective on shares of Vertex Pharmaceuticals from $535.00 to $600.00 and gave the company an “outperform” rating in a research note on Wednesday, September 2nd. Royal Bank Of Canada lifted their target price on shares of Vertex Pharmaceuticals from $576.00 to $600.00 and gave the stock an “outperform” rating in a research note on Tuesday. The Goldman Sachs Group set a $653.00 price target on Vertex Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, September 1st. Rothschild & Co Redburn increased their price target on Vertex Pharmaceuticals from $570.00 to $580.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. Finally, Stifel Nicolaus raised their price objective on Vertex Pharmaceuticals from $500.00 to $563.00 and gave the stock a “hold” rating in a report on Tuesday. One analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $588.56.

Vertex Pharmaceuticals Price Performance

NASDAQ:VRTX traded down $16.27 on Tuesday, reaching $536.88. The stock had a trading volume of 807,723 shares, compared to its average volume of 1,386,333. The company has a market cap of $136.26 billion, a price-to-earnings ratio of 31.20, a P/E/G ratio of 2.54 and a beta of 0.28. The firm’s fifty day moving average is $523.32 and its two-hundred day moving average is $479.96. Vertex Pharmaceuticals has a 12-month low of $403.16 and a 12-month high of $568.67.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings results on Monday, November 2nd. The pharmaceutical company reported $4.76 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.82 by ($0.06). The firm had revenue of $3.44 billion for the quarter, compared to analyst estimates of $3.42 billion. Vertex Pharmaceuticals had a return on equity of 23.09% and a net margin of 35.00%. Vertex Pharmaceuticals’s revenue for the quarter was up 11.8% on a year-over-year basis. During the same period in the prior year, the business earned $4.80 earnings per share. As a group, research analysts forecast that Vertex Pharmaceuticals will post 16.74 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Vertex Pharmaceuticals

Hedge funds have recently modified their holdings of the stock. BlackRock Inc. acquired a new position in shares of Vertex Pharmaceuticals in the 2nd quarter valued at $11,975,849,000. State Street Corp grew its stake in shares of Vertex Pharmaceuticals by 1.2% during the 2nd quarter. State Street Corp now owns 11,871,459 shares of the pharmaceutical company’s stock valued at $5,896,910,000 after buying an additional 141,320 shares during the period. Wellington Management Group LLP grew its stake in shares of Vertex Pharmaceuticals by 1.1% during the 2nd quarter. Wellington Management Group LLP now owns 3,247,658 shares of the pharmaceutical company’s stock valued at $1,613,209,000 after buying an additional 35,069 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of Vertex Pharmaceuticals by 1.0% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,086,683 shares of the pharmaceutical company’s stock worth $1,533,248,000 after buying an additional 29,287 shares during the last quarter. Finally, Bank of America Corp DE acquired a new stake in shares of Vertex Pharmaceuticals during the 2nd quarter worth $1,509,651,000. 90.96% of the stock is owned by institutional investors and hedge funds.

Vertex Pharmaceuticals News Roundup

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Third-quarter revenue increased 11.8% year over year to $3.44 billion, exceeding the $3.42 billion consensus estimate. Growth was supported by the cystic fibrosis franchise and increasing contributions from newer products, including CASGEVY and JOURNAVX. Vertex Reports Third Quarter 2026 Financial Results
• Positive Sentiment: Several analysts raised their price targets after the earnings release. RBC lifted its target to $600 with an “outperform” rating, Wells Fargo raised its target to $650 with an “overweight” rating, Cantor Fitzgerald increased its target to $619 with an “overweight” rating, and Stifel raised its target to $563 while maintaining a “hold” rating. Wells Fargo analyst update
• Positive Sentiment: Management raised full-year 2026 revenue guidance to $13.2 billion-$13.3 billion and highlighted continued portfolio diversification, pipeline progress, and the completed acquisition of Crinetics Pharmaceuticals. Vertex third-quarter results
• Neutral Sentiment: The company’s outlook is broadly in line with Wall Street’s $13.3 billion revenue estimate, limiting the positive impact of the guidance increase. Investors will focus on whether newer launches can offset the eventual transition within the cystic fibrosis business.
• Negative Sentiment: Third-quarter adjusted earnings of $4.76 per share fell short of consensus estimates ranging from $4.82 to $4.92 and declined from $4.80 a year earlier. Vertex misses third-quarter earnings estimates
• Negative Sentiment: Higher investment in new product launches and the Crinetics transaction kept profit growth from matching revenue growth, creating concern that elevated spending could weigh on near-term margins.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated is a global biotechnology company focused on developing and commercializing medicines for serious diseases. Founded in 1989 and headquartered in Boston, Massachusetts, the company applies expertise in the science of human disease to discover therapies that address significant unmet medical needs.

Vertex is best known for its cystic fibrosis portfolio, which includes Kalydeco, Orkambi, Symdeko/Symkevi, and Trikafta/Kaftrio. These medicines target the underlying cause of cystic fibrosis for patients with specific mutations in the CFTR gene.